Loading clinical trials...
Loading clinical trials...
A Randomized Trial of Behavioral Economic Interventions to Reduce CVD Risk
Using a 4-arm, cluster-randomized controlled trial, the investigators will test the effectiveness of different behavioral economic interventions in increasing statin use and reducing LDL cholesterol among patients with poor cholesterol control who are at very high risk for CVD. The investigators will test these approaches among primary care physicians and their patients at very high risk of CVD at Geisinger Health System and University of Pennsylvania outpatient clinics.
Cardiovascular disease (CVD) is the leading cause of death in the United States. Despite strong evidence that reducing low-density lipoproteins (LDL) with statins successfully lowers CVD risk, physicians under-prescribe statins, physicians fail to intensify treatment when indicated, and more than 50% of patients stop taking statins within one year of first prescription, though such therapy typically should be life-long. In this study, we will test the effectiveness of different behavioral economic interventions in increasing statin use and reducing LDL cholesterol among patients with poor cholesterol control who are at very high risk for CVD. The application of conceptual approaches from behavioral economics offers considerable promise in advancing health and health care. Pay for performance initiatives represent one such potential application, but one in which incorporating the underlying psychology of decision makers has not generally been done, and experimental tests have not been conducted. We will test these approaches among primary care physicians and their patients at very high risk of CVD at Geisinger Health System and University of Pennsylvania outpatient clinics. Using a 4-arm, cluster-randomized controlled trial, we aim to answer these questions: \[1\] How does the provision of provider incentives compare to the provision of patient incentives, to a combination of patient and provider incentives, or to no incentives at all? \[2\] Are results sustained after incentives and other interventions are withdrawn? \[3\] How do these approaches compare in implementation, acceptability, cost, and cost-effectiveness?
Age
18 - 80 years
Sex
ALL
Healthy Volunteers
Yes
Harvard Vanguard Medical Associates
Boston, Massachusetts, United States
Geisinger Health System
Danville, Pennsylvania, United States
Unversity of Pennsylvania
Philadelphia, Pennsylvania, United States
Start Date
September 1, 2011
Primary Completion Date
August 1, 2014
Completion Date
August 1, 2014
Last Updated
December 6, 2017
1,503
ACTUAL participants
Behavioral Economic Intervention
BEHAVIORAL
Lead Sponsor
University of Pennsylvania
Collaborators
NCT03372733
NCT07241390
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06909773